MS Treatment May Slow Disability Across Diverse Groups

Credibility

Interest

Share:2 min read

Key Takeaway

In these MS trials, ocrelizumab was linked to less disability worsening across the groups studied, though the result was less certain for Black participants because that group was small.

What They Found

Researchers looked back at two trials of people with relapsing MS, a type of MS with periods of new or worsening symptoms. Among people taking interferon beta-1a, Black and Hispanic or Latino participants were more likely than White participants to have disability that worsened and stayed worse for at least 24 weeks. Participants with more African or Indigenous American genetic ancestry also had a higher risk of this lasting worsening than those with more European ancestry. Black and Hispanic or Latino participants started with higher levels of B cells, immune cells that can play a part in MS. Compared with interferon beta-1a, ocrelizumab lowered B-cell levels in every group and was linked to less lasting disability worsening overall.

Who Should Care and Why

People with relapsing MS may find this study useful when discussing treatment choices with their care team. Black and Hispanic or Latino patients may especially want to ask how their care team tracks changes in walking, hand use, or other daily abilities. Caregivers can help by noting changes that last, rather than assuming a difficult day is the new normal. The findings suggest that ocrelizumab may help people from different backgrounds, but they do not tell any one person which treatment is best for them. If your abilities are changing, bring specific examples—such as trouble climbing stairs—to your next MS visit.

Important Considerations

This was a look back at trial results, so it cannot explain why the groups had different risks of worsening. Only 65 Black participants were included, and the study could not clearly confirm a lower risk of disability worsening with ocrelizumab in that group alone. Group averages cannot predict what will happen to one person, so treatment decisions should also consider your health, goals, and your clinician’s advice.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials MS Progression

Article Topics:

B cellsHispanic/Latinodisease progressionnon-Hispanic Blacknon-Hispanic Whiteocrelizumabrelapsing multiple sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News